257 related articles for article (PubMed ID: 27566310)
21. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma.
Jeong Y; Jung J; Cho B; Kwak J; Jeong C; Kim JH; Park JH; Kim SY; Shim JH; Kim KM; Lim YS; Lee HC; Yoon SM
BMC Cancer; 2018 Apr; 18(1):416. PubMed ID: 29653562
[TBL] [Abstract][Full Text] [Related]
22. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma.
Park JH; Yoon SM; Lim YS; Kim SY; Shim JH; Kim KM; Lee HC; Cho B; Park G; Kim JH
J Gastroenterol Hepatol; 2013 Oct; 28(10):1638-42. PubMed ID: 23621519
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
Kim JW; Seong J; Lee IJ; Woo JY; Han KH
Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
[TBL] [Abstract][Full Text] [Related]
24. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.
Sanuki N; Takeda A; Mizuno T; Oku Y; Eriguchi T; Iwabuchi S; Kunieda E
AJR Am J Roentgenol; 2013 Dec; 201(6):W812-20. PubMed ID: 24261388
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
Lazarev S; Hardy-Abeloos C; Factor O; Rosenzweig K; Buckstein M
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2077-2083. PubMed ID: 30088143
[TBL] [Abstract][Full Text] [Related]
26. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma.
Paik EK; Kim MS; Jang WI; Seo YS; Cho CK; Yoo HJ; Han CJ; Park SC; Kim SB; Kim YH
Radiat Oncol; 2016 Feb; 11():22. PubMed ID: 26896371
[TBL] [Abstract][Full Text] [Related]
27. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.
Sanuki N; Takeda A; Oku Y; Eriguchi T; Nishimura S; Aoki Y; Mizuno T; Iwabuchi S; Kunieda E
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):306-11. PubMed ID: 24411601
[TBL] [Abstract][Full Text] [Related]
28. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.
Qiu H; Moravan MJ; Milano MT; Usuki KY; Katz AW
J Gastrointest Cancer; 2018 Dec; 49(4):463-469. PubMed ID: 28710606
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
30. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
[TBL] [Abstract][Full Text] [Related]
33. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
34. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.
Shanker MD; Liu HY; Lee YY; Stuart KA; Powell EE; Wigg A; Pryor DI
J Gastroenterol Hepatol; 2021 Apr; 36(4):873-884. PubMed ID: 32632941
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease.
Gerum S; Heinz C; Belka C; Walter F; Paprottka P; De Toni EN; Roeder F
Radiat Oncol; 2018 May; 13(1):100. PubMed ID: 29843752
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
Lo CH; Lee HL; Hsiang CW; Chiou JF; Lee MS; Chen SW; Shen PC; Lin CS; Chang WC; Yang JF; Dai YH; Chen CY; Chia-Hsien Cheng J; Huang WY
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):474-484. PubMed ID: 32898609
[TBL] [Abstract][Full Text] [Related]
38. Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system.
Hanazawa H; Takahashi S; Shiinoki T; Park SC; Yuasa Y; Koike M; Kawamura S; Shibuya K
Radiother Oncol; 2017 Apr; 123(1):43-48. PubMed ID: 28285839
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma.
Bae SH; Kim MS; Cho CK; Kim KB; Lee DH; Han CJ; Park SC; Kim YH
J Korean Med Sci; 2013 Feb; 28(2):213-9. PubMed ID: 23400333
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
